MRK  Merck & Company Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.49 (+0.85%)

Growth Price

Overvalued by 18.72%

Stability Price

Overvalued by 59.56%

Company Metrics

  • 31.2 P/E
  • 3.84 P/S
  • 3.44 P/B
  • 1.837 EPS
  • 10.80% Cash ROIC
  • 0.98 Cash Ratio
  • 1.76 / 3.07% Dividend
  • 10.01M Avg. Vol.
  • 166.7B Market Cap.

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Merck & Co., Inc. Earnings: Patent Losses and Competition Weigh on Sales
Motley Fool - Oct 27, 2014
Big pharma giant Merck (NYSE: MRK ) hasn't been shy about the fact that it's in the midst of a multi-year turnaround strategy focused on generating organic and acquired growth, but shareholders sometimes need a reminder that there could be bumps along ...
Merck & Co., Inc. (MRK) Issues FY14 Earnings Guidance - Mideast Time
Merck Gets FDA Breakthrough Therapy Designation For Keytruda In Advanced ... - RTT News
A Quick Look at Merck & Co. Inc.'s Drug Development Pipeline
Motley Fool - Oct 13, 2014
Today, I'd suggest we take a closer look at Merck's (NYSE: MRK ) drug development pipeline in order to get a better idea of how well the company is preparing for its future beyond patent expirations, as well as note which handful of developing drugs ...
Merck & Co., Inc. Tops Earnings, Misses Revenue Estimates
ValueWalk - Oct 27, 2014
Merck & Co., Inc. (NYSE:MKR) released the earnings results from its third quarter this morning before opening bell, posting adjusted earnings of 90 cents per share on $10.56 billion in revenue.
Merck & Co. Inc. (MRK) Among Biggest DJIA Losers on October 27 - Oct 27, 2014
Shares of Merck & Co. Inc. led all laggers on the Dow Monday with a decline of 2.01%. The DJIA closed at 16,817.90, which is a 0.07% change from the previous day's close.
Dow Jones (DJIA) Today: Merck (MRK) Lower -
Equities in Focus - Merck & Co., Inc. (NYSE:MRK), Compugen Ltd. (USA ...
Street Newswire (registration) - Oct 27, 2014
Merck & Co., Inc. (NYSE:MRK) said the U.S. Food and Drug Administration has granted a Breakthrough Therapy Designation to its Keytruda drug to treat non-small cell lung cancer.
Merck & Co. Inc. (MRK) Pulled Back After Q3 Revenues Disappoint
RTT News - Oct 28, 2014
Merck & Co. Inc. (MRK: Quote) reported third quarter adjusted EPS of $0.90 Monday morning, down from $0.92 a year ago. Revenues declined 4 percent to $10.56 billion from $11.03 billion last year.
Fast Money Traders Discuss Merck, Garmin And Sarepta Therapeutics
Benzinga - Oct 28, 2014
On CNBC's Fast Money, Stephanie Link said that Merck & Co., Inc. (NYSE: MRK) posted a fine quarter although the company missed revenue expectations and it narrowed its full year forecast.
Uptrend Stocks At Street: Armstrong World Industries, Inc. (NYSE:AWI), Merck ... - Street Newswire (registration)
Better Dividend Stock: Merck & Co. Inc. or Bristol-Myers Squibb Co.?
DailyFinance - Oct 4, 2014
Dividend stocks are arguably the most critical component to the success of any long-term investor. According to the latest statistics from FactSet, S&P 500 companies paid out a whopping $91.5 billion in dividends during the second quarter, or an ...
Merck & Co. Inc. (MRK) Is Down After Q3 Revenues Fell Short
RTT News - Oct 27, 2014
Merck & Co. Inc. (MRK: Quote) reported third quarter adjusted EPS of $0.90 Monday morning, down from $0.92 a year ago. Revenues declined 4 percent to $10.56 billion from $11.03 billion last year.
Merck & Co., Inc. (NYSE:MRK) 3Q Sales Reflect Unfavorable Divested Products ... - USMarketsDaily (blog)
Merck & Co. (MRK) Announces Quarterly Results - Watch List News (press release)
Merck Conference Call Highlights
Benzinga - Oct 27, 2014
Merck & Co., Inc. (NYSE: MRK) reported its third quarter earnings on Monday. Shares of the company are down 2 percent. Below are some key highlights from its conference call.